Galectin-1 modulates acute and chronic inflammation, and is associated with glucose homeostasis and chronic renal disease. Whether the serum galectin-1 level can predict short-term and longterm renal outcomes after contrast exposure in patients undergoing coronary angiography (CAG) remains uncertain. This study aimed to evaluate the relationship between the serum galectin-1 level and the incidence of contrast-induced nephropathy (CIN), and to investigate the predictive role of the circulating galectin-1 level for renal function decline in patients undergoing CAG. In total, 798 patients who had undergone CAG were enrolled. Baseline creatinine and serum galectin-1 levels were determined before CAG. CIN was defined as an increase in the serum creatinine level of 0.5 mg/dl or a 25% increase from baseline within 48 h after the procedure, and renal function decline was defined as > 30% reduction of the estimated glomerular filtration rate from baseline. All patients were followed for at least 1 year or until the occurrence of death after CAG. Overall, CIN occurred in 41 (5.1%) patients. During a median follow-up period of 1.4 ± 1.1 years, 80 (10.0%) cases showed subsequent renal function decline. After adjustment for demographic characteristics, kidney function, traditional risk factors, and medications, higher galectin-1 levels were found to be associated independently with a greater risk of renal function decline [tertile 2: hazard ratio (HR) 5.56, 95% confidence interval (CI) 1.79-17.22; tertile 3: HR 5.56, 95% CI 1.97-16.32], but not with CIN, regardless of the presence of diabetes. In conclusion, higher baseline serum galectin-1 levels were associated with a greater risk of renal function decline in patients undergoing CAG, but were not associated independently with CIN. Chronic kidney disease (CKD) is a serious public health problem, and its incidence and prevalence are increasing 1. The early detection of individuals at risk of CKD development or progression is especially important, as early-stage CKD is prevalent and contributes greatly to cardiovascular disease. Research clearly indicates that patients with coronary artery disease (CAD) are at increased risk of progressive renal dysfunction 2. These patients may be further exposed to the risk of contrast-induced nephropathy (CIN), which has an incidence rate of 4.4-22.1%, if they undergo coronary angiography (CAG) 3. CIN has traditionally been considered to be a benign and reversible disease, but it may prolong hospital stays and increase in-hospital mortality 4. Accumulating evidence suggests that CIN is related to long-term renal function decline, in addition to short-term outcomes 5,6. Efforts to predict the occurrence of CIN include the development of risk scoring systems composed of baseline risk factors 7 , renal